TAK-418
- Generic Name
- TAK-418
A Study With [18F]MNI-1054 to Determine Lysine -Specific Demethylase 1A (LSD1) Brain Enzyme Occupancy of TAK-418 After Single-Dose Oral Administration in Healthy Participants
Phase 1
Terminated
- Conditions
- Healthy Volunteers
- Interventions
- Drug: [18F]MNI-1054 (radiotracer)
- First Posted Date
- 2019-12-17
- Last Posted Date
- 2021-07-30
- Lead Sponsor
- Takeda
- Target Recruit Count
- 7
- Registration Number
- NCT04202497
- Locations
- 🇺🇸
Invicro, A Konica Minolta Company, New Haven, Connecticut, United States
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Single and Multiple Oral Dose of TAK-418 in Healthy Female Participants
Phase 1
Terminated
- Conditions
- Healthy Volunteers
- Interventions
- Drug: TAK-418 Matching Placebo
- First Posted Date
- 2018-04-18
- Last Posted Date
- 2020-06-16
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT03501069
- Locations
- 🇺🇸
Parexel International, Glendale, California, United States
🇺🇸PRA Health Sciences, Salt Lake City, Utah, United States
A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Ascending Oral Single Dose of TAK-418 in Healthy Participants
- First Posted Date
- 2017-07-24
- Last Posted Date
- 2019-09-09
- Lead Sponsor
- Takeda
- Target Recruit Count
- 40
- Registration Number
- NCT03228433
- Locations
- 🇺🇸
PAREXEL International, Glendale, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath